- Home
- ETNB vs BCYC Comparison
ETNB vs BCYC Comparison
Compare ETNB & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETNB
- BCYC
- Stock Information
- Founded
- ETNB 2018
- BCYC 2009
- Country
- ETNB United States
- BCYC United Kingdom
- Employees
- ETNB 93
- BCYC N/A
- Industry
- ETNB Biotechnology: Pharmaceutical Preparations
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- ETNB Health Care
- BCYC Health Care
- Exchange
- ETNB Nasdaq
- BCYC Nasdaq
- Market Cap
- ETNB 1.2B
- BCYC 701.7M
- IPO Year
- ETNB 2019
- BCYC 2019
- Fundamental
- Price
- ETNB $8.18
- BCYC $9.63
- Analyst Decision
- ETNB Strong Buy
- BCYC Buy
- Analyst Count
- ETNB 9
- BCYC 8
- Target Price
- ETNB $29.63
- BCYC $29.14
- AVG Volume (30 Days)
- ETNB 1.5M
- BCYC 247.7K
- Earning Date
- ETNB 05-08-2025
- BCYC 05-01-2025
- Dividend Yield
- ETNB N/A
- BCYC N/A
- EPS Growth
- ETNB N/A
- BCYC N/A
- EPS
- ETNB N/A
- BCYC N/A
- Revenue
- ETNB N/A
- BCYC $35,275,000.00
- Revenue This Year
- ETNB N/A
- BCYC N/A
- Revenue Next Year
- ETNB N/A
- BCYC $18.29
- P/E Ratio
- ETNB N/A
- BCYC N/A
- Revenue Growth
- ETNB N/A
- BCYC 30.76
- 52 Week Low
- ETNB $5.99
- BCYC $9.58
- 52 Week High
- ETNB $13.71
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- ETNB 42.49
- BCYC 31.44
- Support Level
- ETNB $6.88
- BCYC $9.58
- Resistance Level
- ETNB $9.40
- BCYC $10.84
- Average True Range (ATR)
- ETNB 0.66
- BCYC 0.65
- MACD
- ETNB -0.22
- BCYC -0.00
- Stochastic Oscillator
- ETNB 30.27
- BCYC 2.24
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.